Environmental, Health & Safety

Abmaxis Inc Environmental, Health and Safety Services can help you prevent workplace injuries, illnesses and fatalities, plus the suffering and financial hardship these events can cause for workers, their families and employers. Through our network of qualified, insured and licensed service providers, we can provide your business with comprehensive solutions that help you meet your safety goals.

Research and Pipeline

Abmaxis is focused on discovering, developing and commercializing innovative medicines so people with serious diseases can lead better lives. Our scientists don’t see the impossible as an obstacle; they see it as a good place to start.

These studies are investigating treatments or outcomes that have not all received approval from a health authority. The information presented is not intended to convey conclusions of safety or efficacy. There is no guarantee that the outcome of these studies will result in approval by a health authority.

Working Here

We have some of the industry’s best and brightest people helping us achieve our mission of discovering transformative medicines to help people with serious diseases. Whether they are in the lab, part of our business development team or on the phones with patients, we depend on a talented global workforce to lead the charge as we work toward developing tomorrow’s breakthrough medicines.

Our benefits are very competitive, and we offer challenging and dynamic career opportunities across all areas of our organization while fostering a culture that embraces diversity, authenticity and enthusiasm for lifelong learning.

Abmaxis, Inc. is a privately held biopharmaceutical company. It is dedicated to the discovery, optimization and development of monoclonal antibody (MAb) products for human therapeutics and diagnostics. Our management team with experience in the biotech, pharmaceutical and life science industries. Abmaxis has developed and validated a breakthrough antibody engineering technology platform, Abmaxis in-silico Immunization (AISIMTM), which is used for building an internal product pipeline and for collaborations with global biotech and pharmaceutical partners. The product strategy is to develop a pipeline of products with a spectrum of risk profiles, ranging from next-generation of clinically proven antibody drugs with significantly improved attributes to antibodies against novel targets. Abmaxis collaborates with corporate partners who have proprietary targets or antibodies that require humanization and engineering.




























Menu